Retraction Note: Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma.

IF 3.4 2区医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2024-11-07 DOI:10.1186/s12885-024-13137-1

Yu Zhang, Tianyi Zhang, Yingdong Zhao, Hongdi Wu, Qiang Zhen, Suwei Zhu, Shaoshuai Hou

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

撤稿说明：乳酸脱氢酶D是肺腺癌预后和免疫浸润的新型生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

期刊最新文献

Accurate prediction of the lymph node status in ampullary duodenal carcinoma: potential guidance for clinical management. An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells. Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide. Interim analysis of robot-assisted radical hysterectomy in Japan: a multicenter, prospective interventional single-arm clinical trial. Retraction Note: Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma.